Several brokerages have updated their recommendations and price targets on shares of Valeant Pharmaceuticals International (NYSE: VRX) in the last few weeks:

  • 12/5/2017 – Valeant Pharmaceuticals International was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $19.72 price target on the stock.
  • 12/4/2017 – Valeant Pharmaceuticals International was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $19.18 price target on the stock.
  • 12/3/2017 – Valeant Pharmaceuticals International was given a new $18.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 11/16/2017 – Valeant Pharmaceuticals International was given a new $18.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 11/13/2017 – Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Wells Fargo & Company.
  • 11/13/2017 – Valeant Pharmaceuticals International had its price target raised by analysts at BMO Capital Markets from $16.00 to $17.00. They now have a “market perform” rating on the stock.
  • 11/10/2017 – Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $12.00 price target on the stock.
  • 11/9/2017 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
  • 11/8/2017 – Valeant Pharmaceuticals International was given a new $18.00 price target on by analysts at Royal Bank Of Canada. They now have a “sector perform” rating on the stock.
  • 11/8/2017 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $19.00 price target on the stock.
  • 11/7/2017 – Valeant Pharmaceuticals International was upgraded by analysts at TheStreet from a “d” rating to a “c-” rating.
  • 11/7/2017 – Valeant Pharmaceuticals International was upgraded by analysts at TD Securities from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock.
  • 11/3/2017 – Valeant Pharmaceuticals International was upgraded by analysts at TD Securities from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock.
  • 11/3/2017 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
  • 10/31/2017 – Valeant Pharmaceuticals International was given a new $23.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/30/2017 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $16.00 price target on the stock.
  • 10/27/2017 – Valeant Pharmaceuticals International had its “sell” rating reaffirmed by analysts at Wells Fargo & Company.
  • 10/22/2017 – Valeant Pharmaceuticals International was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a “sell” rating on the stock.
  • 10/20/2017 – Valeant Pharmaceuticals International had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $18.00. They now have a “sector perform” rating on the stock.
  • 10/19/2017 – Valeant Pharmaceuticals International was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $14.26 price target on the stock.
  • 10/13/2017 – Valeant Pharmaceuticals International was downgraded by analysts at Vetr from a “strong-buy” rating to a “hold” rating. They now have a $14.26 price target on the stock.
  • 10/12/2017 – Valeant Pharmaceuticals International was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable. The company reduced its debt by $4.8 billion and expects to meet its target of $5 billion debt reduction ahead of schedule. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Valeant trimmed its guidance due to recent divestitures. However, weakness in the dermatology business persists. Shares have underperformed the industry.”
  • 10/9/2017 – Valeant Pharmaceuticals International had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $18.00 price target on the stock.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at $17.75 on Wednesday. Valeant Pharmaceuticals International, Inc. has a 52 week low of $8.31 and a 52 week high of $18.25. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. The company has a market cap of $6,150.00, a P/E ratio of 2.80, a P/E/G ratio of 0.47 and a beta of -0.22.

In other news, Director John Paulson acquired 344,216 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the purchase, the director now owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc and related companies with MarketBeat.com's FREE daily email newsletter.